KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Deferred Revenue (2016 - 2026)

Pacific Biosciences Of California has reported Current Deferred Revenue over the past 16 years, most recently at $15.9 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 14.95% year-over-year to $15.9 million; the TTM value through Dec 2025 reached $15.9 million, up 14.95%, while the annual FY2025 figure was $15.9 million, 14.95% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $15.9 million at Pacific Biosciences Of California, down from $16.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $32.1 million in Q2 2022 and troughed at $9.5 million in Q2 2021.
  • A 5-year average of $19.3 million and a median of $16.3 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: soared 236.52% in 2022 and later crashed 46.42% in 2023.
  • Year by year, Current Deferred Revenue stood at $11.0 million in 2021, then skyrocketed by 177.84% to $30.5 million in 2022, then crashed by 46.42% to $16.3 million in 2023, then dropped by 15.16% to $13.9 million in 2024, then increased by 14.95% to $15.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for PACB at $15.9 million in Q4 2025, $16.0 million in Q3 2025, and $14.9 million in Q2 2025.